Alpha Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Alpha Biosciences, Inc. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ALPHA BIOSCIENCES. The owner is based in Baltimore, MD.
3651 Clipper Mill Road
Baltimore, MD 21211
Showing of trademarks Trademarks
Trademark Classifications
Alpha Biosciences, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Alpha Biosciences, Inc. have?
Alpha Biosciences, Inc. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Alpha Biosciences, Inc. file in?
Alpha Biosciences, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Alpha Biosciences, Inc.'s most well-known trademarks?
Alpha Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as ALPHA BIOSCIENCES. These are among 1 currently registered trademark in the portfolio.
What is Alpha Biosciences, Inc.'s trademark registration success rate?
Alpha Biosciences, Inc. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.